Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Accumulated Depreciation data on file, last reported at $30.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 29.64% year-over-year to $30.7 million; the trailing twelve-month figure through Mar 2026 stood at $30.7 million (up 29.64% YoY), and the FY2025 full-year result was $29.1 million, up 37.03% from the prior year.
• Accumulated Depreciation advanced to $30.7 million in Q1 2026, from $29.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $30.7 million in Q1 2026 to a low of $6.0 million in Q1 2022.
• A 5-year average of $17.0 million and a median of $15.7 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation soared 120.11% in 2022 and increased 29.64% in 2026, its largest moves.
• Tracing RCKT's Accumulated Depreciation over 5 years: stood at $9.1 million in 2022, then surged by 54.32% to $14.0 million in 2023, then soared by 51.46% to $21.3 million in 2024, then soared by 37.03% to $29.1 million in 2025, then advanced by 5.52% to $30.7 million in 2026.
• Business Quant data shows RCKT's Accumulated Depreciation at $30.7 million in Q1 2026, $29.1 million in Q4 2025, and $27.4 million in Q3 2025.